Update on omalizumab in allergen immunotherapy.
Journal
Current opinion in allergy and clinical immunology
ISSN: 1473-6322
Titre abrégé: Curr Opin Allergy Clin Immunol
Pays: United States
ID NLM: 100936359
Informations de publication
Date de publication:
01 12 2021
01 12 2021
Historique:
pubmed:
23
8
2021
medline:
15
12
2021
entrez:
22
8
2021
Statut:
ppublish
Résumé
To review the most relevant studies in the advancing field of omalizumab in allergen immunotherapy. Omalizumab has been used in combination with inhalant, venom, and food allergen immunotherapy. These studies suggest that omalizumab can decrease the time required to reach maintenance dosing and adverse events. However, severe adverse events do still occur. Limited long-term data suggests that there is a risk for increased reactivity after stopping omalizumab. Omalizumab in conjunction with immunotherapy has shown promising results for the treatment of allergic rhinitis, venom hypersensitivity, and food allergy, especially in the reduction of adverse events. Larger randomized, placebo-controlled trials are needed to better understand optimal dosing and duration, cost--benefit analysis, ideal patients, and long-term benefits. This combination therapy has the potential to improve treatment, particularly for high-risk patients.
Identifiants
pubmed: 34419967
doi: 10.1097/ACI.0000000000000781
pii: 00130832-202112000-00007
doi:
Substances chimiques
Allergens
0
Venoms
0
Omalizumab
2P471X1Z11
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
559-568Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Moreno MA. Atopic diseases in children. JAMA Pediatr 2016; 170:96–196.
Trends in allergic conditions among children: United States, 1997-2011. 2019 [cited 5 February 2020]. Available at: https://www.cdc.gov/nchs/products/databriefs/db121.htm . [Accessed 9 July 2021]
Thomsen SF. Epidemiology and natural history of atopic diseases. Eur Clin Respir J 2015; 2:
Miller J, Blackman AC, Wang HT, et al. Quality of life in food allergic children: results from 174 quality-of-life patient questionnaires. Ann Allergy Asthma Immunol 2020; 124:379–384.
Meltzer EO. Allergic rhinitis: burden of illness, quality of life, comorbidities, and control. Immunol Allergy Clin North Am 2016; 36:235–248.
Gupta R, Holdford D, Bilaver L, et al. The economic impact of childhood food allergy in the United States. JAMA Pediatr 2013; 167:1026–1031.
Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011; 127: (1 Suppl): S1–S55.
Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341:468–475.
Zissler UM, Schmidt-Weber CB. Predicting success of allergen-specific immunotherapy. Front Immunol 2020; 11:1826.
Wise SK, Lin SY, Toskala E, et al. International consensus statement on allergy and rhinology: allergic rhinitis. Int Forum Allergy Rhinol 2018; 8:108–352.
Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev 2010; (8):CD001186.
Boyle RJ, Elremeli M, Hockenhull J, et al. Venom immunotherapy for preventing allergic reactions to insect stings. Cochrane Database Syst Rev 2012; 10:CD008838.
Calderon MA, Alves B, Jacobson M, et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007; (1):CD001936.
Golden DBK, Demain J, Freeman T, et al. Stinging insect hypersensitivity: a practice parameter update. Ann Allergy Asthma Immunol 2017; 118:28–54.
Dantzer JA, Wood RA. Omalizumab as an adjuvant in food allergen immunotherapy. Curr Opin Allergy Clin Immunol 2021; 21:278–285.
Dunlop JH. Oral immunotherapy for treatment of peanut allergy. J Investig Med 2020; 68:1152–1155.
Chinthrajah RS, Cao S, Dunham T, et al. Oral immunotherapy for peanut allergy: the pro argument. World Allergy Organ J 2020; 13:100455.
Wood RA. Food allergen immunotherapy: current status and prospects for the future. J Allergy Clin Immunol 2016; 137:973–982.
Sicherer SH, Warren CM, Dant C, et al. Food allergy from infancy through adulthood. J Allergy Clin Immunol 2020; 8:1854–1864.
Cox L. Biologics and allergy immunotherapy in the treatment of allergic diseases. Immunol Allergy Clin North Am 2020; 40:687–700.
Wood R. Oral immunotherapy for food allergy. J Investig Allergol Clin Immunol 2017; 27:151–159.
Bernstein DI, Wanner M, Borish L, Liss GM. Immunotherapy Committee, American Academy of Allergy, Asthma and Immunology. Twelve-year survey of fatal reactions to allergen injections and skin testing. J Allergy Clin Immunol 2004; 113:1129–1136.
Cox LS, Hankin C, Lockey R. Allergy immunotherapy adherence and delivery route: location does not matter. J Allergy Clin Immunol Pract 2014; 2:156–160.
Tinkelman D, Smith F, Cole WQ, Silk HJ. Compliance with an allergen immunotherapy regime. Ann Allergy Asthma Immunol 1995; 74:241–246.
Bender BG, Oppenheimer J. The special challenge of nonadherence with sublingual immunotherapy. J Allergy Clin Immunol Pract 2014; 2:152–155.
Polk P, Stokes J. Cox LS. Anti-IgE therapy. Immunotherapies for allergic disease 1. Philadelphia: Elsevier Health Sciences; 2019. 355–372.
Kawakami T, Blank U. From IgE to omalizumab. J Immunol 2016; 197:4187–4192.
MacGlashan D. Loss of receptors and IgE in vivo during treatment with anti-IgE antibody. J Allergy Clin Immunol 2004; 114:1472–1474.
MacGlashan DW, Bochner BS, Adelman DC, et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997; 158:1438–1445.
Xolair (Omalizumab) for allergic asthma, nasal polyps, and CIU treatment [Internet]. Genetech USA, Inc; 2021 [cited 2 July 2021]; Available from: https://xolair.com
Dantzer JA, Wood RA. The use of omalizumab in allergen immunotherapy. Clin Exp Allergy 2018; 48:232–240.
El-Qutob D. Off-label uses of omalizumab. Clinic Rev Allerg Immunol 2016; 50:84–96.
Stokes J. Anti-IgE treatment for disorders other than asthma. Front Med 2017; 4:52.
Sicherer SH, Sampson HA. Food allergy: a review and update on epidemiology, pathogenesis, diagnosis, prevention, and management. J Allergy Clin Immunol 2018; 141:41–58.
Gupta RS, Springston EE, Warrier MR, et al. The prevalence, severity, and distribution of childhood food allergy in the United States. Pediatrics 2011; 128:e9–e17.
Burks AW, Sampson HA, Plaut M, et al. Treatment for food allergy. J Allergy Clin Immunol 2018; 141:1–9.
Nelson HS, Lahr J, Rule R, et al. Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. J Allergy Clin Immunol 1997; 99 (6 Pt 1):744–751.
Oppenheimer JJ, Nelson HS, Bock SA, et al. Treatment of peanut allergy with rush immunotherapy. J Allergy Clin Immunol 1992; 90:256–262.
Dantzer JA, Wood RA. Next-generation approaches for the treatment of food allergy. Curr Allergy Asthma Rep 2019; 19:5.
Nurmatov U, Dhami S, Arasi S, et al. Allergen immunotherapy for IgE-mediated food allergy: a systematic review and meta-analysis. Allergy 2017; 72:1133–1147.
Burbank AJ, Sood P, Vickery BP, Wood RA. Oral immunotherapy for food allergy. Immunol Allergy Clin North Am 2016; 36:55–69.
Research C for BE and PALFORZIA. FDA [Internet]. 7 February 2020 [cited 12 February 2020]. Available at: http://www.fda.gov/vaccines-blood-biologics/allergenics/palforzia . [Accessed 9 July 2021]
Leung DYM, Sampson HA, Yunginger JW, et al. Avon Longitudinal Study of Parents and Children Study Team. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 2003; 348:986–993.
Sampson HA, Leung DYM, Burks AW, et al. A phase II, randomized, double-blind, parallel-group, placebo-controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol 2011; 127:1309.e1–1310.e1.
Nadeau KC, Schneider LC, Hoyte L, et al. Rapid oral desensitization in combination with omalizumab therapy in patients with cow's milk allergy. J Allergy Clin Immunol 2011; 127:1622–1624.
Wood RA, Kim JS, Lindblad R, et al. A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy. J Allergy Clin Immunol 2016; 137:1103.e11–1110.e11.
Takahashi M, Soejima K, Taniuchi S, et al. Oral immunotherapy combined with omalizumab for high-risk cow's milk allergy: a randomized controlled trial. Sci Rep 2017; 7:17453.
Martorell-Calatayud C, Michavila-Gómez A, Martorell-Aragonés A, et al. Anti-IgE-assisted desensitization to egg and cow's milk in patients refractory to conventional oral immunotherapy. Pediatr Allergy Immunol 2016; 27:544–546.
Schneider LC, Rachid R, LeBovidge J, et al. A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients. J Allergy Clin Immunol 2013; 132:1368–1374.
Yee CSK, Albuhairi S, Noh E, et al. Long-term outcome of peanut oral immunotherapy facilitated initially by omalizumab. J Allergy Clin Immunol 2019; 7:451.e7–461.e7.
Brandström J, Vetander M, Lilja G, et al. Individually dosed omalizumab: an effective treatment for severe peanut allergy. Clin Exp Allergy 2017; 47:540–550.
Brandström J, Vetander M, Sundqvist A-C, et al. Individually dosed omalizumab facilitates peanut oral immunotherapy in peanut allergic adolescents. Clin Exp Allergy 2019; 49:1328–1341.
MacGinnitie AJ, Rachid R, Gragg H, et al. Omalizumab facilitates rapid oral desensitization for peanut allergy. J Allergy Clin Immunol 2017; 139:873.e8–881.e8.
Bégin P, Dominguez T, Wilson SP, et al. Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using omalizumab. Allergy Asthma Clin Immunol 2014; 10:7.
Andorf S, Purington N, Block WM, et al. Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial. Lancet Gastroenterol Hepatol 2018; 3:85–94.
Andorf S, Purington N, Kumar D, et al. A phase 2 randomized controlled multisite study using omalizumab-facilitated rapid desensitization to test continued vs discontinued dosing in multifood allergic individuals. EClinicalMedicine 2019; 7:27–38.
Azzano P, Paquin M, Langlois A, et al. Determinants of omalizumab dose-related efficacy in oral immunotherapy: evidence from a cohort of 181 patients. J Allergy Clin Immunol 2021; 147:233–243.
Fiocchi A, Vickery BP, Wood RA. The use of biologics in food allergy. Clin Exp Allergy 2021; 51:1006–1018.
Frischmeyer-Guerrerio PA, Masilamani M, Gu W, et al. Mechanistic correlates of clinical responses to omalizumab in the setting of oral immunotherapy for milk allergy. J Allergy Clin Immunol 2017; 140:1043.e8–1053.e8.
Freeman J. Further observations on the treatment of hay fever by hypodermic inoculations of pollen vaccine. Historical document. Ann Allergy 1960; 18:427–434.
Epstein TG, Liss GM, Murphy-Berendts K, Bernstein DI. AAAAI and ACAAI surveillance study of subcutaneous immunotherapy, year 3: what practices modify the risk of systemic reactions? Ann Allergy Asthma Immunol 2013; 110:274–278. 278.e1.
James C, Bernstein DI. Allergen immunotherapy: an updated review of safety. Curr Opin Allergy Clin Immunol 2017; 17:55–59.
Epstein TG, Liss GM, Berendts KM, Bernstein DI. AAAAI/ACAAI Subcutaneous Immunotherapy Surveillance Study (2013–2017): fatalities, infections, delayed reactions, and use of epinephrine autoinjectors. J Allergy Clin Immunol Pract 2019; 7:1996.e1–2003.e1.
Copenhaver CC, Parker A, Patch S. Systemic reactions with aeroallergen cluster immunotherapy in a clinical practice. Ann Allergy Asthma Immunol 2011; 107:441–447.
Windom HH, Lockey RF. An update on the safety of specific immunotherapy. Curr Opin Allergy Clin Immunol 2008; 8:571–576.
Larenas-Linnemann D, Wahn U, Kopp M. Use of omalizumab to improve desensitization safety in allergen immunotherapy. J Allergy Clin Immunol 2014; 133:937.e2–937.e2.
Kuehr J, Brauburger J, Zielen S, et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 2002; 109:274–280.
Kamin W, Kopp MV, Erdnuess F, et al. Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously. Pediatr Allergy Immunol 2010; 21 (1 Pt 2):e160–e165.
Kopp MV, Hamelmann E, Zielen S, et al. DUAL study group. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy 2009; 39:271–279.
Kopp MV, Hamelmann E, Bendiks M, et al. DUAL study group. Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy. Pediatr Allergy Immunol 2013; 24:427–433.
Casale TB, Busse WW, Kline JN, et al. Immune Tolerance Network Group. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2006; 117:134–140.
Massanari M, Nelson H, Casale T, et al. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol 2010; 125:383–389.
Klunker S, Saggar LR, Seyfert-Margolis V, et al. Immune Tolerance Network Group. Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding. J Allergy Clin Immunol 2007; 120:688–695.
Lambert N, Guiddir T, Amat F, Just J. Pretreatment by omalizumab allows allergen immunotherapy in children and young adults with severe allergic asthma. Pediatr Allergy Immunol 2014; 25:829–832.
Bilò BM, Bonifazi F. Epidemiology of insect-venom anaphylaxis. Curr Opin Allergy Clin 2008; 8:330–337.
Sahiner UM, Durham SR. Hymenoptera venom allergy: how does venom immunotherapy prevent anaphylaxis from bee and wasp stings? Front Immunol 2019; 10:1959.
Sturm GJ, Varga E-M, Roberts G, et al. EAACI guidelines on allergen immunotherapy: hymenoptera venom allergy. Allergy 2018; 73:744–764.
Kopač P, Custovic A, Zidarn M, et al. Biomarkers of the severity of honeybee sting reactions and the severity and threshold of systemic adverse events during immunotherapy. J Allergy Clin Immunol Pract 2021; 9:3157.e5–3163.e5.
Golden DBK. Venom immunotherapy: questions and controversies. Immunol Allergy Clin North Am 2020; 40:59–68.
Kontou-Fili K. High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis. Allergy 2008; 63:376–378.
Galera C, Soohun N, Zankar N, et al. Severe anaphylaxis to bee venom immunotherapy: efficacy of pretreatment and concurrent treatment with omalizumab. J Investig Allergol Clin Immunol 2009; 19:225–229.
Gülsen A, Ruëff F, Jappe U. Omalizumab ensures compatibility to bee venom immunotherapy (VIT) after VIT-induced anaphylaxis in a patient with systemic mastocytosis. Allergol Select 2021; 5:128–132.
Boni E, Incorvaia C, Mauro M. Dose-dependence of protection from systemic reactions to venom immunotherapy by omalizumab. Clin Mol Allergy 2016; 14:14.
Palgan K, Bartuzi Z, Gotz-Zbikowska M. Treatment with a combination of omalizumab and specific immunotherapy for severe anaphylaxis after a wasp sting. Int J Immunopathol Pharmacol 2014; 27:109–112.
Schulze J, Rose M, Zielen S. Beekeepers anaphylaxis: successful immunotherapy covered by omalizumab. Allergy 2007; 62:963–964.
da Silva EN, Randall KL. Omalizumab mitigates anaphylaxis during ultrarush honey bee venom immunotherapy in monoclonal mast cell activation syndrome. J Allergy Clin Immunol Pract 2013; 1:687–688.
Soriano Gomis V, Gonzalez Delgado P, Niveiro Hernandez E. Failure of omalizumab treatment after recurrent systemic reactions to bee-venom immunotherapy. J Investig Allergol Clin Immunol 2008; 18:225–226.
Stretz E, Oppel EM, Räwer H-C, et al. Overcoming severe adverse reactions to venom immunotherapy using anti-IgE antibodies in combination with a high maintenance dose. Clin Exp Allergy 2017; 47:1631–1639.